Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis

Expert Opinion on Emerging Drugs

Volumn 12, Issue 2, 2007, Pages 229-252

  Bedlack, Richard S ^a   Traynor, Bryan J ^b   Cudkowicz, Merit E ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ALS; Amyotropic lateral sclerosis; MND; Motor neuron disease; Neuroprotection

Indexed keywords

3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; AEOL 10150; ANTIOXIDANT; ANTISENSE OLIGONUCLEOTIDE; ARIMOCLOMOL; ARUNDIC ACID; ARYLBUTYRIC ACID DERIVATIVE; CELASTROL; CELECOXIB; CREATININE; ETIRACETAM; GLATIRAMER; GLUTAMATE CARBOXYPEPTIDASE II INHIBITOR; GPI 16072; GRANULOCYTE COLONY STIMULATING FACTOR; MEMANTINE; MINOCYCLINE; NIMESULIDE; NORPHENAZONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT SCATTER FACTOR; RILUZOLE; TALAMPANEL; TAMOXIFEN; THALIDOMIDE; TREHALOSE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; ARTIFICIAL VENTILATION; ASTHENIA; BREAST CANCER; CLINICAL TRIAL; DIET THERAPY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DIZZINESS; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DYSMENORRHEA; ENDOCRINE DISEASE; EPILEPSY; EXCITOTOXICITY; FEEDING APPARATUS; GASTROINTESTINAL DISEASE; GENE EXPRESSION; GENE MUTATION; HUMAN; IMMUNE DYSREGULATION; LEPROSY; MULTIPLE SCLEROSIS; NERVE FIBER TRANSPORT; NEUROPROTECTION; OSTEOARTHRITIS; OXIDATIVE STRESS; PALLIATIVE THERAPY; PATHOGENESIS; PROTEIN AGGREGATION; REVIEW; RNA INTERFERENCE; SINGLE DRUG DOSE; STROKE; SURVIVAL RATE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; HUMANS; MOTOR NEURON DISEASE; NEUROPROTECTIVE AGENTS; SIGNAL TRANSDUCTION;

EID: 34250750301     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.12.2.229     Document Type: Review

References (153)

1. ROWLAND LP, SCHNEIDER N: Amyotrophic lateral sclerosis. New. Engl. J. Med. (2001) 344(22):1691-1700.
2. ROWLAND LP: How amyotrophic lateral sclerosis got its name. Arch. Neurol. (2001) 58:512-515.
3. BROOKS BR: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors. J. Neurol. Sci. (1994) 124(s):96-107.
4. HOUSEHAM E, SWASH M: Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement? J. Neurol. Sci. (2000) 180:76-81.
5. CHIO A: ISIS survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis. J. Neurol. (1999) 246(SIII):1-5.
6. CHIO A: Update on ISI survey: europe, north america and south america. Amyotroph. Lateral Scler. Other Motor Neuron Disord. (2000) 1(S1):9-11.
7. SWINGLER RJ, FRASER H, WARLOW CP: Motor neuron disease and polio in Scotland. JNNP (1992) 55:1116-1120.
8. TRAYNOR BJ, CODD MB, CORR B, FORDE C, FROST BA, HARDIMAN O: Incidence and prevalence of ALS in Ireland, 1995-1997. Neurology (1999) 52:504.
9. PARALS: Incidence of ALS in Italy. Neurology (2001) 56:239-244.
10. LOGROSCINO G, BEGHI E, ZOCCOLELLA S et al.: Incidence of amyotrophic lateral sclerosis in southern Italy: a population based study. JNNP (2005) 76:1094-1098.
11. NEARY D, SNOWDEN JS, MANN D: Cognitive change in motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). J. Neurol. Sci. (2000) 180:15-20.
12. ZOCCOLELLA SG, PALAGANO G, FRADDOSIO A et al.: ALS-plus: 5 cases of concomitant amyotrophic lateral sclerosis and parkinsonism. Neurol. Sci. (2004) 23(s2):123-124.
13. DEL AGUILA MA, LONGSTRETH WT JR, MCGUIRE V, KOEPSELL TD, VAN BELLE G: Prognosis in amyotrophic lateral sclerosis. A population-based study. Neurology (2003) 60:813-819.
14. MILLUL A, BEGHI E, LOGROSCINO G, MICHELI A, VITELLI E, ZARDI A: Survival of patients with amyotrophic lateral sclerosis in a population-based registry. Neuroepidemiology (2005) 25(3):114-119.
15. GROHME K, MARAVIC MV, GASSER T, BORASIO GD: A case of amyotrophic lateral sclerosis with very slow progression over 44 years. Neuromuscul. Disord. (2001) 11(4):414-416.
16. PUGLIATTI M, ROSATI G, CARTON H: The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol (2006) 13:700-722.
17. JOHNSON CA, STANTON BR, TURNER MR et al.: Amyotrophic lateral sclerosis in an urban setting: a population based study of innner city london. J. Neurol. (2006) 253:1642-1643.
18. ANDERSEN P: Amyotrophic lateral sclerosis genetics with mendelian inheritance. In: Amyotrophic Lateral Sclerosis. Brown RH, Swash M, Pasinelli P (Eds), Informa Healthcare, London UK (2006):187-208. •• Comprehensive recent review of FALS.
19. MAJOR-KRAKAUER D, WILLEMS PJ, HOFMAN A: Genetic epidemiology of amyotrophic lateral sclerosis. Clin. Genet. (2003) 63(2):83-101.
20. BRUIJN L, CUDKOWICZ M: Therapeutic targets for amyotrophic lateral sclerosis: current treatments and prospects for more effective therapies. Expert Rev. Neurotherapeutics (2006) 6(3):417-428.
21. YANG Y, HENTATI A, DENG H et al.: The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. (2001) 29:160-165.
22. HADANO S, HAND C, OSUGA H et al.: A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat. Genet. (2001) 29:166-173.
23. HENTATI A, OUAHCHI K, PERICAK-VANCE MA et al.: Linkage of a commoner form of recessive amyotrophic lateral sclerosis to chromosome 15q15-q22 markers. Neurogenetics (1998) 2(1):55-60.
24. HONG S, BROOKS SR, HUNG W et al.: X-linked dominant locus for late-onset familial amyotrophic lateral sclerosis. Soc. Neurosci. Abst. (1998) 24:478.
25. JULIEN J, KRIZ J: Transgenic mouse models of amyotrophic lateral sclerosis. Biochemimica et Biophysica Acta (2006) 1762:1013-1024.
26. BOILLEE S, VANDE VELDE C, CLEVELAND D: ALS: a disease of motor neurons and their nonneuronal neighbors. Neuron (2006) 52:39-59. •• Outstanding review, focussing on role of multiple cell types.
27. ALEXANDER MD, TRAYNOR BJ, MILLER N et al.: "True" sporadic als associated with a novel SOD-1 mutation. Ann. Neurol. (2002) 52(5):680-683.
28. SIMPSON C, AL-CHALABI A: Amyotrophic lateral sclerosis as a complex genetic disease. Biochimica et Biophysica Acta (2006) 1762:973-985. •• Recent comprehensive review of genetic susceptibility.
29. ISHIGAKI S, NIWA J, ANDO Y et al.: Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett. (2002) 531:354-358.
30. SCHYMICK J, SCHATZ S, HON-CHUNG F et al.: Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. (2007) 6(4):322-328.
31. TANAKA F, JIANG YM, YAMAMOTO M et al.: Gene expresión profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. (2006) 7(S1):9.
32. SARIS C, VAN VUGHT P, YIGITTOP H et al.: Molecular pathway analysis of amyotrophic lateral sclerosis by genome-wide expression profiling of human blood. Amyotroph. Lateral Scler. (2006) 7(S1):11.
33. PLATO CC, GARRUTO RM, GALASK D et al.: Amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am. J. Epidemiol. (2003) 157:149-157.
34. SUNDAR P, CHANG-EN Y, WEIVA S et al.: Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Hum. Mol. Genet. (2007) 16(3):295-306.
35. COX PA, SACKS OW: Cycad neurotoxin, consumption of flying foxes, and ALS/PDC disease in guam. Neurology (2002) 58:956-959.
36. KWANG C, CRAIG U, LEE C et al.: Cycad neurotoxin, consumption of flying foxes, and ALS/PDC disease in guam. Neurology (2002) 59:1664-1665.
37. CHO A, BENZI G, DOSSENA M et al.: Severely increased risk for amyotrophic lateral sclerosis among Italian professional football players. Brain (2005) 128:472-476.
38. WEISSKOPF M, O'REILLY E, MCCULLOUGH M et al.: Prospective study of military service and risk of amyotrophic lateral sclerosis. Neurology (2005) 64:32-37.
39. HALEY RW: Excess incidence of ALS in young Gulf War veterans. Neurology (2003) 61:750-756.
40. HORNER RD, KAMINS KG, FEUSSNER JR et al.: Excess incidence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology (2003) 61:742-749.
41. NELSON L, MCGUIRE V: Epidemiology of amyotrophic lateral sclerosis. In: Amyotrophic Lateral Sclerosis. Brown RH, Swash M, Pasinelli P (Eds), Informa Healthcare, London UK (2006):25-42. •• Recent comprehensive review of possible environmental triggers.
42. MCGUIRE V, LONGSTRETH W, KOEPSELL T, VAN BELLE G: Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. Neurology (1996) 12:219-228.
43. MILLER RG, MOORE DH, GELINAS D et al.: Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology (2001) 56:843-848.
44. DESNUELLE C, DIB M, GARREL C et al.: A double-blind, placebo-controlled trial of a-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. (2001) 2:9-18.
45. SHEFNER J, CUDKOWICZ M, SCHOENFELD D et al.: A clinical trial of creatine in ALS. Neurology (2004) 63:1656-1661.
46. CUDKOWICZ M, SHEFNER J, SCHOENFELD D et al.: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology (2003) 61:456-464.
47. CUDKOWICZ M, SHEFNER J, SCHOENFELD D et al.: Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. (2006) 60:22-31.
48. LAU J, CONWIT R, MILLER R, CUDKOWICZ M: Therapeutic trials in amyotrophic lateral sclerosis: past, present, future. In: Amyotrophic Lateral Sclerosis. Brown RH, Swash M, Pasinelli P (Eds), Informa Healthcare, London, UK (2006):335-356.
49. BENOIT E, ESCANDE D: Riluzole specifically blocks inactivated Na channels in myelinated nerve fiber. Pflugers Arch. (1991) 419:603-609.
50. ZONA C, SINISCALCHI A, MERCURI NB et al.: Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience (1998) 85:931-938.
51. STEFANI A, SPADONI F, BERNARDINI G: Differential inhibition by riluzole, lamotrigine and phenytoin of sodium and potassium currents in cultured rat cortical neurons. Neuroscience (1998) 85:931-938.
52. GURNEY ME, FLECK TJ, HIMES CS, HALL ED: Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology (1998) 50(1):62-66.
53. BENSIMON G, LACOMBLEZ L, MEININGER V: A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Eng. J. Med. (1994) 330:585-591.
54. LACOMBLEZ L, BENSIMON G, LEIGH P et al.: Dose ranging study of riluzole in amyotrophic lateral sclerosis. Lancet (1996) 347:1425-1431.
55. SORENSON E: An acute, life-threatening, hypersensitivity reaction to riluzole. Neurology (2006) 67:2260-2261.
56. PONGRATZ D, NEUNDORFER B, FISCHER W: German open label trial of riluzole 50mg b.i.d. in amyotrophic lateral sclerosis (ALS). J. Neurol. Sci. (2000) 180:82-85.
57. OLIVER D, BORASIO G: Palliative care and quality of life in amyotrophic lateral sclerosis. In: Amyotrophic Lateral Sclerosis. Brown RH, Swash M, Pasinelli P (Eds), Informa Healthcare, London, UK (2006):357-362.
58. VAN DEN BERG JP, KALMIJN S, LINDEMAN E et al.: Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology (2005) 65(8):1264-1267.
59. MILLER RG, ROSENBERG JA, GELINAS DF et al.: Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence based review), report of the quality standards subcommittee of the american academy of neurology: ALS practice parameters task force. Neurology (1999) 52(7):1311-1323. • Guide to optimal care of patients with ALS.
60. LEIGH N, ABRAHAMS S, AL-CHALABI A et al.: The management of motor neurone disease. J. Neurol. Neurosurg. Psychiatry (2003) 74:32-47. • Guide to optimal care of patients with ALS.
61. ENG D: Management guidelines for motor neurone disease patients on non-invasive ventilation at home. Palliat. Med. (2006) 20:69-79.
62. MAZZINI L, CORRA T, ZACCALA M, MORA G, DEL PIANO M, GALANTE M: Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. Neurology (1995) 242:695-698.
63. ABOUSSOUAN LS, KHAN SU, MEEKER DP, STELMACH K, MITSUMOTO H: Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann. Intern. Med. (1997) 127:450-453.
64. TRAYNOR BJ, ALEXANDER M, CORR B, FROST E, HARDIMAN O: Effect of a multidisciplinary amyotrophic (ALS) clinic on ALS survival: a population based registry 1996-2000. J. Neurol. Neurosurg. Psychiatry (2003) 74(9):1258-1261.
65. ANDERSEN PM: Amyotrophic lateral sclerosis associated with mutations in the CuZn superoxide dismutase gene. Curr. Neurol. Neurosci. Rep. (2006) 6(1):37-46.
66. CLEMENT AM, NGUYEN MD, ROBERTS EA et al.: Wild-type non-neuronal cells extend survival of SOD-1 mutant motor neurons in ALS mice. Science (2003) 302:113-117.
67. BOILEE S, YAMANAKA K, LOBSIGER C et al.: Onset and progression in inherited ALS detetmined by motor neurons and microglia. Science (2006) 312:1389-1392.
68. YOSHIHARA T, ISHIGAKI S, YAMAMOTO M et al.: Differential expression of inflammation-and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. (2002) 80:158-167.
69. FERRAIULO L, HEATH P, HOLDEN H et al.: Gene expression profile of spinal motor neurons in the G93A SOD1 mouse model of ALS at different time points. Amyotroph. Lateral Scler. (2006) 7(S1):10.
70. KUDO L, KARSTEN S, WIEDAUPAZOS M: Whole genome microarray analysis of motor neuron vulnerability in G93A-SOD1 and P301L-Tau transgenic mouse models of als. Amyotroph. Lateral Scler. (2001) 7(S1):10.
71. BARBER S, MEAD R, SHAW P: Oxidative stress in als: a mechanism of neurodegeneration and a therapeutic target. Biochimica et Biophysica Acta (2006) 1762:1051-1067. •• Recent comprehensive review of oxidative stress hypothesis.
72. RYU H, SMITH K, CAMELO S et al.: Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. (2005) 93(5):1087-1098.
73. BRUIJN L, HOUSEWEART MK, KATO S et al.: Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science (1998) 281:1851-1854.
74. DURHAM HD, ROY J, DONG L, FIGLEWICZ DA: Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J. Neuropathol. Exp. Neurol. (1997) 56:523-530.
75. CLEVELAND DW, LIU J: Oxidation versus aggregation - how do SOD1 mutants cause ALS? Nat. Med. (2000) 6:1320-1321.
76. JOHNSTON J, DALTON M, GURNEY M, KOPITO R: Formation of high molecular weight complexes of mutant Cu,Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA (2000) 97:12571-12576.
77. WANG J, XU G, SLUNT HH: Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA. Neurobiol. Dis. (2005) 20:943-952.
78. SATO T, NAKANISHI T, YAMAMOTO Y et al.: Rapid disease progression correlates with instability of mutant SOD1 in familial ALS. Neurology (2001) 65:1954-1957.
79. VAN DEN BOSCH L, VAN DAMME P, BOGAERT E, ROBBERECHT W: The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis. Biochimica et Biophysica Acta (2006) 1762:1068-1082. •• Recent comprehensive review of excitotoxicity hypothesis.
80. ALEXANDER G, DEITCH J, SEEBURGER J, DEL VALLE L, HEIMAN-PATTERSON T: Elevated cortical extracellular fluid glutamate in transgenic mice expressing human mutant (G93A) superoxide dismutase. J. Neurochem. (2000) 74:1666-1673.
81. SHAW P, FORREST V, RICHARDSON J, WASTELL H: CSF and plasma amino acid levels in motor neuron disease: elevation of CSF glutamate in a subset of patients. Neurodegeneration (1995) 4:209-216.
82. COURATIER P, HUGON J, SINDOU P, VALLAT J, DUMAS M: Cell culture evidence for neuronal degeneration in amyotrophic lateral sclerosis being linked to glutamate AMPA/kainate receptors. Lancet (1993) 341:265-268.
83. SPENCER P, ROY D, LUDOLPH A, HUGON J, DWIVEDI M, SCHAUMBURG H: Lathyrism: evidence for role of the neuroexcitatory amino acid BOAA. Lancet (1986) 2:1066-1067.
84. ROTHSTEIN JD, VAN KAMMEN M, LEVEY A et al.: Selective loss of glutamate transporter GLT-1 in ALS. Ann. Neurol. (1995) 38:73-84.
85. ROTHSTEIN JD, PATEL S, REGAN MR et al.: β-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 433:73-77.
86. TATENO M, SADAKATA H, TANAKA M et al.: Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum. Mol. Genet. (2004) 13:2183-2196.
87. MANFREDI G, BEAL M: Mitochondrial dysfunction and energy metabolism in amyotrophic lateral sclerosis. In: Amyotrophic Lateral Sclerosis. Brown RH, Swash M, Pasinelli P (Eds), Informa Healthcare, London, UK (2006):323-331. •• Recent comprehensive review of mitochondrial hypothesis.
88. KONG J, XU Z: Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. (1998) 18:3241-3250.
89. KIRBY J, HALLIGAN E, BAPTISTA M et al.: Mutant SOD1 alters the motor neuron transcriptase: implications for familial ALS. Brain (2005) 128:1686-1706.
90. MOISSE K, STRONG M: Innate immunity in amyotrophic lateral sclerosis. Biochimica et Biophyska Acta (2006) 1762:1083-1093. •• Recent comprehensive review of neuroinflammation hypothesis.
91. ALEXIANU M, KOZOVSKA M, APPEL S: Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology (2001) 57:1282.
92. DRACHMAN D, ROTHSTEIN J: Inhibition of cyclooxygenate-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann. Neurol. (2000) 48(5):792-795.
93. URUSHITANI M, SILK A, SAKURAI T, NUKINA N, TAKAHASHI R, JULIEN J: Chromogranin-median secretion of mutant superoxide dismutase proteins linked to amyotrophic lateral sclerosis. Nat. Neurosci. (2005) 9:108-118.
94. XIAO S, MCLEAN J, ROBERTSON J: Neuron intermediate filaments and ALS: a new look at an old question. Biochimica et Biophysica Acta (2006) 1762:1001-1012. •• Recent comprehensive review of cytoskeletal derangement hypothesis.
95. AL-CHALABI A, ANDERSEN P, NILSSON P et al.: Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum. Mol. Genet. (1999) 8:157-164.
96. PULS I, JONNAKUTY C, LAMONTE B et al.: Mutant dynactin in motor neuron disease. Nat. Genet. (2003) 33:455-456.
97. STERNECK E, KAPLAN DR, JOHNSON P: Interleukin-6 induces expression of peripherin and cooperates with Trk receptor signaling to promote neuronal differentiation in PC12 cells. J. Neurochem. (1996) 67:1365.
98. CHEVALIER-LARSEN E, HOLZBAUR E: Axonal transport and neurodegenerative disease. Biochimka et Biophysica Acta (2006) 1762:1094-1108. •• Recent comprehensive review of defective axonal transport hypothesis.
99. EKESTERN E: Neurotrophic factors and amyotrophic lateral sclerosis. Neurodegener. Dis. (2004) 1:88-100.
100. STORKEBAUM E, LAMBRECHTS D, DEWERCHIN M et al.: Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat. Neurosci. (2004) 8:85-92.
101. SENDTNER M: Damaging secretions: chromogranins team up with mutant SOD1. Nat. Neurosci. (2006) 9:12-14.
102. LI M, ONA VO, GUEGAN C et al.: Functional role of caspase 1 and 3 in ALS. Science (2000) 288:335-339.
103. SPOOREN W, HENGERER B: DNA laddering and caspase 3-like activity in the spinal cord of a mouse model of familial amyotrophic lateral sclerosis. Cell Mol. Biol. (2000) 46:63.
104. MARTIN LJ: Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution to a programmed cell death mechanism. J. Neuropathol. Exp. Neurol. (1999) 58:459-471.
105. HE B, STRONG M: Motor neuronal death in sporadic amyotrophic lateral sclerosis (ALS) is not apoptotic: a comparative study of ALS and chronic aluminum chloride neurotoxicity in new Zealand white rabbits. Neuropathol. Appl. Neurobiol. (2000) 26:150-160.
106. TRAYNOR BJ, BRUIJN L, CONWIT F et al.: Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology (2006) 67:20-27. • Recent review of potiential ALS therapies.
107. SHOEMAKER JL, SEELY KA, REED R, CROW P, PRATHER L: The cb2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. Atlanta USA Society for Neuroscience Meeting (2006).
108. SMITH RA, MILLER TM, YAMANAKA K et al.: Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. (2006) 116(8):2290-2297.
109. CUDKOWICZ M, SHEFNER M, SIMPSON E et al.: A multicenter, dose ranking safety and pharmacokinetic study of arimoclomol in ALS. Amyotrophic Lateral Sclerosis (2006) 7(S1):113.
110. KIPIANI K, KIAEI M, CHEN J, CALINGASAN N, BEAL M: Celasterol blocks motor neuron cell death and extends life in transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. (2004) 90(S1):92.
111. MATTHEWS RT, YANG L, BROWNE S, BAIK M, BEAL M: Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc. Natl. Acad. Sci. USA (1998) 95:8892-8897.
112. ROTHSTEIN J: Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann. Neurol. (2003) 53:423-426.
113. GROENVELD G, VELDINK J, VAN DER TWEEL I et al.: A randomized, sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. (2003) 53:437-445.
114. KLIVENYI P, KIAEI M, GARDIAN G et al.: Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of ALS. J. Neurochem. (2004) 88:576-582.
115. KIM S, KIM H, KOH S et al.: Effectiveness of recombinant human erythropoietin therapy in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. (2006) 7(S1):9.
116. BLAIR M, PEASE M, HAMMOND J et al.: Effect of glatiramer acetate on primary and secondary degeneration of retinal ganglion cells in the rat. Investig. Ophthalmol. and Vis. Sci. (2005) 46:884-890.
117. GORDON PH, DOORISH C, MONTES J et al.: Randomized, controlled phase II trial of glatiramer acetate in ALS. Neurology (2006) 66:1117-1119.
118. PITZER C, KRUGER C, KIRSCH F et al.: G-CSF protects motoneurons and counteracts denervation atrophy in a mouse model of ALS. Atlanta USA Society for Neuroscience Meeting (2006).
119. AOKI M, ISHIGAKI I, NAGAI M et al.: Intrathecal delivery of hepatocyte growth factor at the onset of paralysis slows disease progression in a rat model of ALS. Amyotrophic Lateral Sclerosis (2006) 7(S1):41.
120. FUNAKOSHI H, NAKAMURA T: Hepatocyte growth factor as a novel neurotrophic factor for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. (2006) 7(S1):41.
121. BEDLACK R: A pilot trial of levetiracetam for cramps, spasticity and neuroprotection in patients with motor neuron disease. Northeast ALS Consortium Meeting. Boston USA (2006).
122. SMITH K: The effects of levetiracetam on the sod-1 mutant mouse model of amyotrophic lateral sclerosis/motor neuron disease. Unpublished data on file at UCB Pharma.
123. YOSHINO H, KIMURA A: Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. (2006) 7:241-245.
124. POMPL P, HO L, BIANCHI M et al.: A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. (2003) 17:725-727.
125. CUDKOWICZ ME, ANDRES PI, SCHOENFELD D et al.: Saftey and dose escalating study of oral sodium phenylbutyrate in subjects with ALS. Amyotroph. Lateral Scler. (2006) 7(S1):9.
126. DANZEISEN R, SCHWALENSTOECKER B, GILLARDON F et al.: Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its non-dopaminergic enantiomer SND919CL2x. J. Pharm. Exp. Therap. (2006) 316:189-199.
127. LORENZL S, NARR S, ANGELE B et al.: The matrix metalloproteinase inhibitor Ro 26-2853 extends survival in transgenic ALS mice. Exp. Neurol. (2006) 200:166-171.
128. XU L, YAN J, CHEN D et al.: Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation (2006) 82:865-875.
129. KIAEI M, PETRI S, KIPIANI K et al.: Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci. (2006) 26:2467-2473.
130. ABITBOL J, CUVIER V, BORDET T, DROUOT C, BERNA P, PRUSS R: Safety and pharmacokinetics of repeated doses of TRO-19622, a drug candidate for the treatment of amyotrophic lateral sclerosis and spinal muscular atrophy. Amyotroph. Lateral Scler. (2006) 7(S1):9.
131. SUGAI F, YAMAMOTO Y, MIYAGUCHI K et al.: Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur. J. Neurosci. (2004) 20:3179-3183.
132. BENATAR M, POLAK M, KAPLAN S, GLASS J: Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible? J. Neurol. Sci. (2004) 251:3-9.
133. PASINETTI G, UNGAR L, LANGE J et al.: Identification of potential CSF biomarkers in ALS. Neurology (2006) 66:1218-1222. •• Implicates biomarkers that may facilitate diagnosis and facilitate more efficient trial designs.
134. CHEUNG Y, GORDON P, LEVIN B: Selecting promising ALS therapies in clinical trials. Neurology (2006) 67:1748-1751.
135. ROSEN DR, SIDDIQUE T, PATTERSON D et al.: Mutations in CuZn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature (1993) 362:59-62.
136. HAND CK, KHORIS J, SALACHAS F et al.: A novel locus for familial amyotrophic lateral sclerosis on chromosome 18q. Am. J. Hum. Genet. (2002) 70:251-256.
137. CHANCE P, RABIN B, RYAN S et al.: Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. Am. J. Hum. Genet. (62):633-640.
138. ABALKHAIL H, MITCHELL J, HABGOOD J, ORRELL R, DE BELLEROCHE J: A new familial amyotrophic lateral sclerosis locus on chromosome 16q12.1-16q12.2. Am. J. Hum. Genet. (2003) 73:383-389.
139. SAPP P, HOSLER B, MCKENNA-YASEK D et al.: Identification of two novel loci for dominantly inherited familial amyotrophic lateral sclerosis. Am. J. Hum. Genet. (2003) 73:397-403.
140. NISHIMURA A, MITNE-NETO M, SILVA H et al.: A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis. Am. J. Hum. Genet. (2004) 75:822-831.
141. GREENWAY MJ, ALEXANDER MD, ENNIS S et al.: A novel candidate region for ALS on chromosome 14q11.2. Neurology (2004) 63:1936-1938.
142. GREENWAY M, ANDERSEN P, RUSS C et al.: ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis. Nat. Genet. (2006) 38:411-413.
143. MOMENI P, SCHYMICK J, JAIN S et al.: Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD. BMC Neurol. (2006) 6:44.
144. MORITA M, AL-CHALABI A, ANDERSEN P et al.: A locus on chromosome 9p confers susceptibility to ALS and frontotemporal dementia. Neurology (2006) 66:839-844.
145. HUTTON M, LENDON C, RIZZU P et al.: Association of missense and 5′splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 393:702-705.
146. WOOD JD, BEAUJEUX TP, SHAW PJ: Protein aggregation in motor neurone disorders. Neuropathol. Appl. Neurobiol. (2003) 29:529-545.
147. ROSS C, POIRIER M: Protein aggregation and neurodegenerative disease. Nat. Med. (2004) 10(s):S10-S17.
148. STRONG M, KESAVAPANY S, PANT H: The pathobiology of amyotrophic lateral sclerosis: a proteinopathy? J. Neuropathol. Exp. Neurol. (2005) 64:649-664. • Recent comprehensive review of protein aggregation hypothesis.
149. http.//www.neuro.wusd.edu/neuromuscular/synmot.html Neuromuscular Disease Center of Washington University (2006)
150. http.//www.drugstore.com/pharmacy/prices/drugprice.asp?ndc= 00075770060&trx=1Z5006 Drug Store website (2006).
151. http://www.aeoluspharma.com/AEOL10150dev.php AEOLUS Pharmaceuticals website (2006).
152. http://www.clinicaltrials.gov/ct/show/NCT00355576?order=21 The National Institute of Health Clinical Trials website, Combination Therapy Selection Trial (2006).
153. http://www.alsconsortium.org/index.html Northeast ALS Consortium website (2006).